IBRI IN THE NEWS: Biosciences Institute Develops Diagnosis Technologies
June 15, 2020
INDIANAPOLIS - The Indiana Biosciences Research Institute in Indianapolis has completed development of two technologies it says could diagnose diseases faster and with more accuracy. The IBRI says its BioMEMs and SIERRA Reagent technologies could help patients get treatment more quickly.
The institute says BioMEMs is a system that uses micro-sized components to reduce cost and improve sensitivity of diagnostic tests, and SIERRA Reagent is the platform that helps diagnose infections and other diseases from a single cell. When used together, the IBRI says they are more sensitive and provide results faster than other available products on the market today.
"My research passion has always been to identify immunity markers for infections in diabetes and obesity. So, when I had the opportunity at the IBRI to lead a team whose mission was to develop technologies that would diagnose diseases more efficiently and effectively, I took it. I'm proud to say we achieved our goal two years ahead of schedule with the completion of and testing of BioMEMs and SIERRA," said Dr. Michael Pugia, investigator and director of the IBRI's Bioanalytical Technologies group.
To read the full article, go to Inside INdiana Business.